Treatment of Ocular Manifestations of Behcet's Disease.

Abstract: Purpose: Ocular lesions are the major cause of morbidity in Behcet's Disease. Cytotoxic drugs are the main therapeutic agents. We present here a comparative study of 8 methods in 1056 treated cases. Materials & Methods: In an open, non­randomized control study, Pulse Cyclophosphamide (PCP), low dose PCP (LDP), oral Cyclophosphamide (OCP), weakly methotrexate (MTX), chlorambucil (CHL), cyclosporine A (CYA), azathioprine (AZA), and combination therapy with LDP and MTX (COM) were used in a standard protocol. Inclusion Criteria were: 1- Fulfilling the Classification Tree criteria. 2- Presence of active posterior uveitis (PU) and/or retinal vasculitis (RV). A Total Inflammatory Activity Index (TIAI) was calculated for each patient on the inflammatory state of the anterior chamber, the uvea, and the retina. Visual acuity (VA): was calculated by the Snellen chart. The threshold level for improvement or aggravation was set to 30% change from the entry data. The Improvement or stabilization of VA or TIAI is expressed in 2 ways: 1- p value of the mean before and after the treatment compared by the Student paired t test. 2- Percentage and the confidence interval of those cured, improved, or stabilized. Mean Duration: Ocular manifestations in months. FU: Follow-up in months Conclusion: All treatment methods did approximately the same with no statistically significant difference between them.